OncoMatch/Clinical Trials/NCT07320105
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
Is NCT07320105 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Tislelizumab + platinum-based chemotherapy and Tislelizumab + platinum-based chemotherapy + focal radiotherapy for non-small cell lung cancer.
Treatment: Tislelizumab + platinum-based chemotherapy · Tislelizumab + platinum-based chemotherapy + focal radiotherapy — This study will be conducted at Fujian Provincial Cancer Hospital. Its main goals are to evaluate the progression-free survival (PFS) and safety of postoperative immunotherapy combined with radiotherapy in patients with high-risk stage Ⅲ N2 non-small cell lung cancer after surgery. It will also assess the overall survival (OS) of this treatment as a secondary goal. This study has been approved by the Medical Ethics Committee of Fujian Provincial Cancer Hospital, and the rights and safety of all participants will be fully protected during the trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiotherapy
Cannot have received: chemotherapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
Normal major organ function, with basically normal results of blood routine, blood biochemistry and coagulation function tests
Kidney function
Normal major organ function, with basically normal results of blood routine, blood biochemistry and coagulation function tests
Liver function
Normal major organ function, with basically normal results of blood routine, blood biochemistry and coagulation function tests
Cardiac function
No severe underlying diseases or severe cardiopulmonary dysfunction; Poorly controlled cardiovascular symptoms or diseases (e.g., NYHA class II or higher heart failure, unstable angina, myocardial infarction within 1 year, uncontrolled arrhythmia) [excluded]
Normal major organ function, with basically normal results of blood routine, blood biochemistry and coagulation function tests; No severe underlying diseases or severe cardiopulmonary dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify